What Bristol Myers Squibb's Quarter ended Sep 30, 2026 10-Q says: 4 signals
Bristol Myers Squibb filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses capex increase, international growth and product launch.
Get Bristol Myers Squibb's live signals in Claude or ChatGPT, or by API
What changed at Bristol Myers Squibb this week? Use Autobound signals for bms.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 12
Source: Autobound Signal API · 118 signals tracked for Bristol Myers Squibb · updated
10-Q · latest 10
What Bristol Myers Squibb's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 4 signals
FDA Approves Zenbexus in August 2026 for Multiple Myeloma Following Prior Lines
Bristol-Myers Squibb received U.S. FDA approval in August 2026 for Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for adult patients with multiple myeloma.
Bristol-Myers Squibb is evolving and streamlining its enterprise operating model across R&D, manufacturing, commercial, and other functions, expecting annual cost savings of approximately $2.0 billion by the end of 2027 under its updated 2023 Restructuring Plan.
$2B
annual cost savings by the end of 2027
In August 2026, the company announced plans to build a new multi-modal manufacturing campus in Houston, Texas, and a new radiopharmaceutical manufacturing facility in Whitestown, Indiana.
International Revenues Increased 5% Year-to-Date Reaching $10,700 Million
International revenues reached $10,700 million for the nine months ended September 30, 2026, up 5% compared to $10,193 million in the prior year period.
5%
year-to-date increase in international revenues
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 2 signals
Bristol-Myers Squibb targets $2.0B annual cost savings by end of 2027 via restructuring plan
The company is evolving and streamlining its enterprise operating model across R&D, manufacturing, commercial, and other functions under its updated 2023 Restructuring Plan to realize $2.0 billion in annual savings by 2027.
$2B
annual cost savings by the end of 2027 from strategic productivity initiative and restructuring
HHS selects Orencia for negotiated government-set prices beginning in 2028 under IRA
Under the Inflation Reduction Act, HHS announced maximum fair prices for Eliquis starting January 1, 2026, Pomalyst starting January 1, 2027, and selected Orencia in January 2026 for government-set pricing beginning in 2028.
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 6 signals
FDA and EC approvals received for Opdivo and Sotyktu in March 2026
Bristol-Myers Squibb secured multiple regulatory approvals in March 2026, including FDA approval of Opdivo combination for cHL, EC approval for Opdivo in cHL, and FDA approval of Sotyktu for active PsA.
IRA Imposes Government-Set Drug Pricing for Eliquis, Pomalyst, and Orencia
Under the Inflation Reduction Act, HHS announced maximum fair prices for Eliquis starting January 1, 2026 and Pomalyst starting January 1, 2027, and selected Orencia for price negotiation starting in 2028.
Incurred $410 Million in IPRD Impairment Charges in Q1 2026
Research and development expenses increased by $393 million in Q1 2026 primarily due to $410 million in IPRD impairment charges.
$410M
IPRD impairment charges
BMS expands operating model restructuring targeting $2.0 billion annual savings by end of 2027
Bristol-Myers Squibb is streamlining its enterprise operating model across R&D, manufacturing, commercial, and other functions under its updated 2023 Restructuring Plan.
$2B
expected annual cost savings by the end of 2027 from ongoing strategic productivity initiative
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Bristol Myers Squibb earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Partnering with Anthropic and NVIDIA for AI drug developmentBMS is collaborating with Anthropic and NVIDIA to embed enterprise AI across its entire research and development value chain. The initiative aims to reduce drug testing timelines by 20% to 30% and cut target selection to lead molecule identification time in half. Additionally, a recent agreement with Tempus Patmos focuses on modeling large neuroscience datasets to predict clinical trial outcomes. | |
| Targeting $2B operational efficiencies by end of 2027BMS is actively executing its strategic productivity initiative aimed at generating $2.0 billion in cost and operational efficiencies by the end of 2027. Operating expenses were $4.1 billion in Q3, and management noted these reductions provide the financial flexibility to redeploy capital into growth portfolio assets and pipeline R&D. Vendors delivering enterprise automation, R&D trial... | |
| Rewiring clinical trial design and drug discovery via AIBMS is actively rewiring how it operates across R&D to accelerate clinical development cycles, optimize trial design, and raise the probability of technical success. The initiative involves standardizing data architecture and integrating predictive AI models across preclinical discovery and clinical operations. Software vendors offering automated clinical trial management, trial site... | |
| Upcoming European LOE to cause $1.5B-$2.0B Eliquis step downBMS faces significant revenue headwinds from the upcoming loss of exclusivity (LOE) for Eliquis in Europe. Management projects an annual revenue step-down of $1.5 billion to $2.0 billion in 2027 as generic erosion impacts the legacy portfolio. While Q3 Eliquis sales rose 26% to $4.7 billion, total legacy portfolio revenue is expected to decline 3% to 5% across 2026, forcing a major commercial... | |
| Accelerated approval and launch of first CELMoD SymvexisBMS secured FDA accelerated approval and initiated the commercial launch of Symvexis for multiple myeloma, marking the market entry of its first CELMoD oral therapy. Early adoption is expanding across both community and academic centers as the company aims to displace legacy regimens. Sales teams in oncology distribution and clinical enablement have immediate opportunities supporting this rollout. | |
| Growth portfolio expands 12% with 8 blockbuster medicinesBMS now counts 8 growth portfolio medicines annualizing above $1 billion each based on Q3 run rates, powering a 12% segment increase to $7.7 billion. Notable product growth includes Breyanzi up 48% to $526 million, Camzyos up 42% to $420 million, and Reblozyl up 22% to $750 million. Strong commercial momentum will support continued marketing and clinical trial services procurement. |
Signal API · MCP
Track Bristol Myers Squibb with the Signal API
One POST /v1/companies/enrich call with bms.com returns Bristol Myers Squibb 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Bristol Myers Squibb 10-Q
When did Bristol Myers Squibb file its latest 10-Q?
What did Bristol Myers Squibb disclose in its latest 10-Q?
What did Bristol Myers Squibb say on its recent earnings calls?
Where can I read Bristol Myers Squibb's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .